Enter inventor name

Hemaka Anthony Rajapakse

USPTO Granted Patents = 14 (Patent Applications = 2)

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 21(Granted Patents)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

Sunesis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2016

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9233977 - Leucine-rich repeat kinase enzyme activity (2016-01-12),

2. 8492387 - 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease (2013-07-23),

3. 8394837 - 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease (2013-03-12),

4. 8338614 - Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease (2012-12-25),

5. 8211904 - Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease (2012-07-03),

6. 8008315 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease (2011-08-30),

7. 7968571 - 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease (2011-06-28),

8. 7951949 - Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease (2011-05-31),

9. 7847100 - 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease (2010-12-07),

10. 7829597 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease (2010-11-09),

11. 7820674 - Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease (2010-10-26),

12. 7678783 - Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease (2010-03-16),

13. 7354942 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease (2008-04-08),

14. 7348448 - Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease (2008-03-25),

Title: Hemaka Anthony Rajapakse: Innovator in Pharmaceutical Research

Introduction

Hemaka Anthony Rajapakse is a notable inventor based in Wyncote, PA (US), recognized for his significant contributions to pharmaceutical research. With a total of 14 patents to his name, he has made strides in developing innovative treatments for various diseases.

Latest Patents

Among his latest patents is a groundbreaking invention related to leucine-rich repeat kinase enzyme activity. This patent discloses compounds of Formula (I) and their pharmaceutically acceptable salts, which are crucial for treating diseases amenable to inhibition of LRRK2 kinase activity, such as Parkinson's disease. Another significant patent involves 2-aminoimidazole beta-secretase inhibitors, aimed at treating Alzheimer's disease. This invention focuses on compounds that inhibit the beta-secretase enzyme, providing new avenues for treatment in conditions where this enzyme plays a critical role.

Career Highlights

Hemaka has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His experience in these organizations has allowed him to contribute to the development of innovative therapies that address critical health challenges.

Collaborations

Throughout his career, Hemaka has collaborated with esteemed colleagues, including Philippe G. Nantermet and Harold G. Selnick. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Hemaka Anthony Rajapakse stands out as a dedicated inventor whose work in pharmaceutical research has the potential to impact the treatment of serious diseases. His innovative patents and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com